Insider Monkey
RBC Sees Durable Growth Profile at Becton Dickinson (BDX), Raises Target
➖
AI Sentiment
Neutral
4/10
- Home
- BDX
as of 01-02-2026 3:35pm EST
$195.22
+$1.15
+0.59%
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
| Founded: | 1897 | Country: | United States |
| Employees: | 72000 | City: | FRANKLIN LAKES |
| Market Cap: | 55.5B | IPO Year: | 1962 |
| Target Price: | $213.13 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 5.82 | EPS Growth: | -0.68 |
| 52 Week Low/High: | $162.29 - $251.99 | Next Earning Date: | 02-04-2026 |
| Revenue: | $21,840,000,000 | Revenue Growth: | 8.24% |
| Revenue Growth (this year): | 4.02% | Revenue Growth (next year): | 3.37% |
AI-Powered BDX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 72.55%
72.55%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Becton Dickinson and Company (BDX)
Feld Michael
Sell
EVP, CRO & Pres. Life Sciences
BDX Dec 26, 2025
Avg Cost/Share
$196.08
Shares
74
Total Value
$14,509.92
Owned After
16,506
SEC Form 4
Garrison Michael David
Sell
EVP & Pres Med.Essntl&BioPharm
BDX Dec 17, 2025
Avg Cost/Share
$196.03
Shares
629
Total Value
$123,302.87
Owned After
13,105
SEC Form 4
Feld Michael
Sell
EVP, CRO & Pres. Life Sciences
BDX Dec 1, 2025
Avg Cost/Share
$193.36
Shares
75
Total Value
$14,502.00
Owned After
16,506
SEC Form 4
SCOTT BERTRAM L
Sell
Director
BDX Nov 7, 2025
Avg Cost/Share
$176.58
Shares
217
Total Value
$38,317.86
Owned After
35,816
SEC Form 4
Feld Michael
Sell
EVP & President, Life Sciences
BDX Oct 27, 2025
Avg Cost/Share
$186.01
Shares
57
Total Value
$10,602.57
Owned After
16,506
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Feld Michael | BDX | EVP, CRO & Pres. Life Sciences | Dec 26, 2025 | Sell | $196.08 | 74 | $14,509.92 | 16,506 | |
| Garrison Michael David | BDX | EVP & Pres Med.Essntl&BioPharm | Dec 17, 2025 | Sell | $196.03 | 629 | $123,302.87 | 13,105 | |
| Feld Michael | BDX | EVP, CRO & Pres. Life Sciences | Dec 1, 2025 | Sell | $193.36 | 75 | $14,502.00 | 16,506 | |
| SCOTT BERTRAM L | BDX | Director | Nov 7, 2025 | Sell | $176.58 | 217 | $38,317.86 | 35,816 | |
| Feld Michael | BDX | EVP & President, Life Sciences | Oct 27, 2025 | Sell | $186.01 | 57 | $10,602.57 | 16,506 |
Latest Becton Dickinson and Company News
BDX Breaking Stock News: Dive into BDX Ticker-Specific Updates for Smart Investing
Simply Wall St.
An Intrinsic Calculation For Becton, Dickinson and Company (NYSE:BDX) Suggests It's 40% Undervalued
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Becton Dickinson Insiders Added US$1.36m Of Stock To Their Holdings
📊
AI Sentiment
Positive
7/10
Compare BDX vs Leading Stocks
See how BDX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BDX Becton Dickinson and Company - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.